Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 1:00 PM ET. The event will take place virtually, and a live webcast will be available on Milestone's website. An archived replay will also be accessible for 30 days post-presentation. Milestone focuses on developing cardiovascular medicines and operates in both Canada and the U.S. For more details, visit www.milestonepharma.com.